Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Dec 8, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥18 years of age
- • Endoscopic and/or histological confirmed diagnosis of UC
- • UC disease extent proximal to the rectum (ie, left-sided colitis or pancolitis)
- • Moderately to severely active UC, defined by an endoscopic Mayo score of ≥ 2
- • Indication for receiving filgotinib treatment
- Exclusion Criteria:
- • Pregnancy
- • Inability to give informed consent
- • Proctitis only
- • Ongoing gastroenteritis
- • (Sub)total colectomy
- • Obesity (BMI \>35 kg/m²)
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam Zuidoost, Noord Holland, Netherlands
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials